Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

76.90
-5.0000-6.11%
Volume:683.63K
Turnover:53.81M
Market Cap:5.25B
PE:-24.76
High:83.65
Open:81.00
Low:76.51
Close:81.90
52wk High:122.20
52wk Low:45.91
Shares:68.29M
Float Shares:55.48M
Volume Ratio:0.53
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-3.1100
ROE:-90.45%
ROA:-27.51%
PB:37.76
PE(LYR):-24.73

Loading ...

Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial

Reuters
·
Mar 17

Rhythm Pharmaceuticals Shares Fall About 13% to $78.58 After the Bell Following Announcement That Emanate Phase 3 Trial Didn't Meet Primary Endpoints

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals reports Phase 3 EMANATE trial misses primary endpoints for setmelanotide across four genetic substudies

Reuters
·
Mar 17

Rhythm Pharmaceuticals Inc: Plans to Continue Analysis of Emanate Dataset & Evaluate Potential Clinical Development Paths Forward

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals Inc - No New Safety Signals Observed With Setmelanotide in Emanate Trial

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals price target raised to $143 from $136 at Wells Fargo

TIPRANKS
·
Mar 12

A Look At Rhythm Pharmaceuticals (RYTM) Valuation After New Trial Data Earnings And Financing Updates

Simply Wall St.
·
Mar 10

Rhythm Pharmaceuticals Corporate Controller and CAO Christopher Paul German Disposes of Common Shares

Reuters
·
Mar 07

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)

TIPRANKS
·
Mar 06

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 02

Rhythm Says New Late-Stage Data for Obesity Drug Shows Strong Weight Loss, Hunger Reduction

MT Newswires Live
·
Mar 02

Rhythm Pharmaceuticals price target lowered to $140 from $141 at Canaccord

TIPRANKS
·
Mar 02

Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential

Simply Wall St.
·
Mar 02

Rhythm announces additional data from Phase 3 trial of setmelanotide

TIPRANKS
·
Mar 02

BRIEF-Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026

Reuters
·
Mar 02

Rhythm Pharmaceuticals reports positive Phase 3 TRANSCEND data for setmelanotide in acquired hypothalamic obesity

Reuters
·
Mar 02

Rhythm Pharmaceuticals Announces Additional Positive Data From Phase 3 Transcend Trial of Setmelanotide in Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Mar 02

Rhythm Pharmaceuticals Inc - Primary Endpoint Achieved With 16.4% Bmi Reduction

THOMSON REUTERS
·
Mar 02

Rhythm Pharmaceuticals Inc - Pdufa Goal Date for Setmelanotide Is March 20, 2026

THOMSON REUTERS
·
Mar 02

Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies

TIPRANKS
·
Feb 28